We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 5.00 | 0.30% | 1,645.50 | 1,645.50 | 1,646.00 | 1,646.50 | 1,635.00 | 1,638.50 | 132,334 | 08:18:38 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.71 | 67.54B |
From Apr 2019 to Apr 2024
By Adam Clark
GlaxoSmithKline PLC (GSK.LN) said on Monday that its majority-owned ViiV Healthcare joint venture has reported positive interim results from a study of dolutegravir, a treatment for adults with both HIV and tuberculosis.
GSK said the ViiV phase IIIb study of dolutegravir showed the treatment was effective and well-tolerated in patients already receiving rifampin medication for tuberculosis.
John Pottage, chief scientific and medical officer of ViiV, said, "Tuberculosis remains the leading cause of death among people living with HIV, accounting for around one in three AIDS-related deaths. Concurrent treatment of TB and HIV remains a challenge as it is compounded by drug interactions, overlapping toxicities and immune reconstitution inflammatory syndrome."
GSK has a 78% stake in ViiV, while Shionogi & Co. Ltd. (4507.TO) and Pfizer Inc. (PFE) have minority holdings.
Shares in GlaxoSmithKline closed up 18.80 pence, or 1.5%, at 1308.80 pence on Monday.
Write to Adam Clark at adam.clark@dowjones.com
(END) Dow Jones Newswires
March 05, 2018 12:41 ET (17:41 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
